Randomized, Double-Blind, Multicenter Study to Evaluate Efficacy and Safety of Intravenous Iclaprim Versus Vancomycin in the Treatment of Hospital-Acquired, Ventilator-Associated, or Health-Care-Associated Pneumonia Suspected or Confirmed to be Due to Gram-Positive Pathogens.

Trial Profile

Randomized, Double-Blind, Multicenter Study to Evaluate Efficacy and Safety of Intravenous Iclaprim Versus Vancomycin in the Treatment of Hospital-Acquired, Ventilator-Associated, or Health-Care-Associated Pneumonia Suspected or Confirmed to be Due to Gram-Positive Pathogens.

Discontinued
Phase of Trial: Phase II

Latest Information Update: 26 Jul 2017

At a glance

  • Drugs Iclaprim (Primary) ; Vancomycin
  • Indications Gram-positive infections; Nosocomial pneumonia
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Arpida
  • Most Recent Events

    • 26 Jul 2017 Primary endpoint (Efficacy: Clinical cure rate - comparison of the two iclaprim dosing regimens versus vancomycin) has not been met, as per results published in the Clinical Therapeutics.
    • 26 Jul 2017 Results published in the Clinical Therapeutics
    • 24 Mar 2012 Additional locations (Estonia, Latvia, Lithuania) added as reported by European Clinical Trials Database record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top